Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: EC:2.3.1.108 (
TAT
)
2,389
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
We tested the activity of a p53 carboxy-terminal peptide containing the
PARC
-interacting region in cancer cells with wild type cytoplasmic p53. Peptide delivery was achieved by fusing it to the
TAT
transduction domain (
TAT
-p53-C-ter peptide). In a two-hybrid assay, the tetramerization domain (TD) of p53 was necessary and sufficient to bind
PARC
. The
TAT
-p53-C-ter peptide disrupted the
PARC
-p53 complex. Peptide treatment caused p53 nuclear relocation, p53-dependent changes in gene expression and enhancement of etoposide-induced apoptosis. These studies suggest that
PARC
-interacting peptides are promising candidates for the enhancement of p53-dependent apoptosis in tumors with wt cytoplasmic p53.
...
PMID:Activation of p53-dependent responses in tumor cells treated with a PARC-interacting peptide. 1823 Mar 39
